Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04797858 · ClinicalTrials.gov registry record · NA
COVID-19 Self-Testing Through Rapid Network Distribution
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 792
- Enrollment target
NCT04797858: Completed NA study, sponsored by University of Pennsylvania.
NCT04797858 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 792 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04797858, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 792 participants
- Enrollment target
Study Summary
COVID-19, the coronavirus disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has led to a global pandemic and has exacerbated existing health inequities among vulnerable populations. Despite higher rates of COVID-19 in Black and Latinx individuals compared to White individuals, rates of testing in predominately non-White, low-income communities are significantly lower than in high-income areas. Self-testing, where individuals collect their own samples, is now feasible for the detection of SARS-CoV-2. One promising approach to increase test uptake is the secondary distribution of self-testing kits, where an individual distributes tests to contacts in their social network and encourages them to self-test. The central hypothesis of this clinical trial is that the secondary distribution of SARS-CoV-2 self-tests can significantly expand test uptake among underserved populations. To test this hypothesis, the investigators will conduct a 1:1 randomized controlled trial that will assess a self-testing intervention that promotes the secondary distribution of SARS-CoV-2 test kits compared with test referrals, with a focus on reaching underserved populations.
Primary Outcome
The primary outcome is the proportion of study participants who distributed tests/referrals to least two network contacts who completed testing. This outcome will be measured by number of participants with at least 2 unique network contacts who completed a test linked to a study participant by week 8. The investigators will test for differences in the primary outcome between the two study arms.
Interventions
- BEHAVIORAL COVID-19 self-test
- BEHAVIORAL COVID-19 test referral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 792 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2023-11-29 |
| Phase | NA |
What the finished NCT04797858 record still lists
NCT04797858 is an interventional study that assigns participants to a tested intervention. The registered 792 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 2 interventions - of which COVID-19 self-test is the first listed.
NCT04797858 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04797858 about?
NCT04797858 is a clinical study titled "COVID-19 Self-Testing Through Rapid Network Distribution". COVID-19, the coronavirus disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has led to a global pandemic and has exacerbated existing health inequities among vulnerable populations. Despite higher rates of COVID-19 in Black and Latinx individuals compared to White indiv...
What is the current status of trial NCT04797858?
This trial is currently completed. It is a NA study. The enrollment target is 792 participants. The study started on 2021-05-05. Estimated completion is 2023-11-29.
What interventions are being tested in trial NCT04797858?
The interventions under investigation include: COVID-19 self-test (BEHAVIORAL), COVID-19 test referral (BEHAVIORAL).
Who is sponsoring clinical trial NCT04797858?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04797858's enrollment target sits among peer trials
792 140th of 2000 higher than 1,860 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- NCT05866081 · 792 participants · NA
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
- NCT06722352 · 792 participants · NA
Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI